Mainline Biosciences has a total of 12 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2017. It filed its patents most often in United States, Canada and China. Its main competitors in its focus markets pharmaceuticals and biotechnology are SILVER CREEK PHARMACEUTICALS INC, PESTKA BIOMEDICAL LAB INC and XOMA (US) LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 3 | |
#2 | Canada | 2 | |
#3 | China | 2 | |
#4 | EPO (European Patent Office) | 2 | |
#5 | WIPO (World Intellectual Property Organization) | 2 | |
#6 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Zhang Junge | 12 |
#2 | Yan Liang Zeng | 10 |
#3 | Yan Liang | 2 |
Publication | Filing date | Title |
---|---|---|
US2020155697A1 | Selective CXCR4 Binding Peptide Conjugate and Methods for Making and Using the Same | |
CN111183146A | Conjugates that bind CXCR4 with high affinity selectivity and methods of use thereof | |
US2018066021A1 | CXCR4 antagonists and methods of use |